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Abstract
Background: Since 1989 when the first 146 HIV positives in China were identified, Dehong Prefecture had been
one of the areas hardest-hit by HIV in China. The local and national governments have put substantial financial
resources into tackling the HIV epidemic in Dehong from 2004. The objective of this study was to track dynamic
changes in HIV-1 prevalence and incidence among five focal populations in Dehong and to assess the impact of
HIV prevention and control efforts.
Methods: Consecutive cross-sectional surveys conducted in five focal populations between 2004 and 2008.
Specimens seropositive for HIV were tested with the BED IgG capture enzyme immunoassay to identify recent
seroconversions (median, 155 days) using normalized optical density of 0.8 and adjustments.
Results: From 2004 to 2008, estimated annual HIV incidence among injecting drug users (IDUs) decreased
significantly [from 15.0% (95% CI = 11.4%-18.5%) in 2004 to 4.3% (95% CI = 2.4%-6.2%) in 2008; trend test
P < 0.0001]. The incidence among other focal populations, such as HIV discordant couples (varying from 5.5% to
4.7%), female sex workers (varying from 1.4% to 1.3%), pregnant women (0.1%), and pre-marital couples
(0.2 to 0.1%) remained stable. Overall, the proportion of recent HIV-1 infections was higher among females than
males (P < 0.0001).
Conclusions: The HIV epidemic in Dehong continued to expand during a five-year period but at a slowing rate
among IDUs, and HIV incidence remains high among IDUs and discordant couples. Intensive prevention measures
should target sub-groups at highest risk to further slow the epidemic and control the migration of HIV to other
areas of China, and multivariate analysis is needed to explore which measures are more effective for different
populations.
Background
Dehong Prefecture lies on the China-Myanmar border
in Yunnan Province, which is one of the areas hardest-
hit by HIV in China [1]. Since 1989 when the first 146
HIV-infected injection drug users (IDUs) were identified
in Dehong, this area has reported a cumulative total of
14,903 HIV/AIDS cases through 2008, representing 6.2%
of China’s reported HIV/AIDS cases though it has only
0.08% of China’s population.
According to sentinel surveillance data, IDUs repre-
sent the largest single group of HIV-infected persons in
Dehong [1]. From IDUs, the epidemic has spread to
other groups, particularly female sex workers (FSWs).
Sexual transmission is now the most common mode of
HIV transmission in Yunnan Province [2]. In order to
limit transmission of HIV to a minimum, a number of
targeted intervention services including needle exchange
programs, methadone maintenance therapy, condom
distribution, voluntary counseling and testing, anti-
retroviral therapy, prevention of mother-to-child
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use and HIV have been introduced [3]. Since 2004, the
local and national governments have put substantial
financial resources into tackling the HIV epidemic in
Dehong. In order to assess the impact of HIV preven-
tion and control efforts, we examined the trend in HIV
incidence among five focal populations: IDUs, discor-
dant couples, FSWs, pregnant women, and couples
going for pre-marital counseling and testing. These
five populations represent the main targeted incidence
surveillance populations in Dehong during this time
period.
The incidence of HIV has recently been estimated
using laboratory-based assays that distinguish between
recent and long-term HIV infection. This method avoids
some of the biases inherent in testing participants
repeatedly in a prospective cohort where the actual fol-
low-up process can influence behaviors. Specimens are
collected from serial cross-sectional surveillance surveys
[4]. In the present study, we used the BED capture
enzyme immunoassay (BED-CEIA) for the detection of
recent HIV infection and the calculation of incidence
estimates [5-7]. The assay (using suitable adjustments
described in the methods) has previously been validated
in study populations in China, in which the difference
between HIV incidence estimated by BED and prospec-
tive cohort studies was similar [8,9]. BED has proven
sensitive for the detection of HIV recent infection but
are vulnerable to misclassifying established infections as
recent [10], though test efficiency can be improved with
adjustments for false positives due to low CD4+ cell
count, antiretroviral use, and advanced clinical disease
[11-13]. This study explored the HIV incidence trend in
Dehong to assess the impact of HIV preventive efforts
and to guide future prevention and control efforts in
China.
Methods
Study design and target population
Consecutive cross-sectional surveys were conducted
each year between 2004 and 2008 among IDUs, discor-
dant couples, FSWs, and pregnant women and com-
pared with sentinel surveillance site trend data over the
same time span. Between 2006 and 2008, couples pre-
senting for pre-marital counseling and testing were also
included to represent young adults in the general
population.
IDUs
Serial cross-sectional surveys were conducted in all five
detoxification centers in Dehong (there is one detoxifi-
cation center in each of five counties: namely Lianghe,
Luxi, Longchuan, Ruili and Yinjiang). IDUs at the detox-
ification centers are estimated to represent about 25% of
all drug users in Dehong Prefecture.
Discordant couples
The partners of HIV positive individuals were recruited
into the discordant couple group if they tested HIV
seronegative.
Female sex workers
Data from FSWs were collected annually from five cities
and counties in Dehong at the FSWs’ workplace. There
were an estimated 160 fixed and 10 flowing FSW work-
places in Dehong by the end of 2008. More than 85% of
FSWs in Dehong were believed to work at fixed sites.
Pregnant women
HIV counseling and testing was implemented for all
pregnant women at each of the 3 levels of the health
care system (county MCH hospital, township hospitals,
and village health centers) in Dehong. In 2008, an esti-
mated 95% of pregnant women accepted HIV testing in
antenatal clinics.
Couples in pre-marital testing
From 2006, routine ‘opt-out’ HIV testing was added to
standard pre-marital health check-ups in hospitals in
five counties, and the acceptance rate for HIV testing
was more than 95%.
Data collection
The questionnaires were designed and administered by
staff from the Prefecture Center for Disease Control
(CDC). Oral informed consent was obtained for the
questionnaire and for the blood collection from all parti-
cipants, with the interviewer certifying oral consent by
signing the form. The data were collected as part of rou-
tine HIV surveillance activities, including information on
behavioral, social and demographic indicators and ART
use. Clients were informed as to the purpose of the
blood test and conventional HIV antibody test results
were provided to all subjects. While a large proportion
of approached subjects agreed to testing, we do not
have precise data on the number of refusals. All HIV-
positive patients were referred for free HIV care and
treatment according to the China “Four Frees and One
Care” policy [14]. The study was approved by the Insti-
tutional Review Board of the Yunnan CDC.
Laboratory methods
Two enzyme-linked immunosorbent assays (Anti-
Human Immunodeficiency Virus 1+2 Antibody ELISA
K i t ,B e i j i n gB G I - G B IB i o t e c hC o . ,L t d . ,B e i j i n g ,C h i n a )
and a Western blot (Genelabs Diagnostics Pte. Ltd., Sin-
gapore) confirmatory test were performed to determine
HIV status. HIV-positive patients were also checked for
CD4+ T cell count. HIV-positive patients for whom the
CD4+ T cell count was ≤200 and who self-identified as
on antiretroviral treatment (ART) were excluded from
further HIV incidence testing. The known long-term
HIV infection and AIDS cases were also not included.
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infection using BED-CEIA, as described elsewhere [15].
Samples positive on BED assay testing were categorized
as recent infection. Results from BED tests were not
provided to participants because the assay has only been
validated for population-level testing [11,16].
Data Analysis
Survey and serological data were independently double-
entered into EpiInfo™ software (version 3.4.3-CDC-Atlanta,
GA, USA). Participants’ data were cross-referenced with
China’s Information System for HIV/AIDS Prevention and
Control national HIV surveillance database. Participants
were determined not to have new infections if their name,
birthday, and address matched a person already entered in
the national HIV system. Data were evaluated for con-
gruency using EpiData software (EpiData 3.0 for Win-
dows™, The EpiData Association Odense, Denmark).
Statistical Program for Social Sciences (SPSS, version 15.0)
software was used for all statistical analyses. The BED-esti-
mated HIV incidences were calculated by a Microsoft
Excel-based program for automated results interpretation
prepared for the study according to Calypte’s instructions.
An ODn of 0.8 corresponds to mean seroconversion dura-
tion of 155 days and the samples with an ODn of <0.8 are
considered to be from individuals with recent infection.
Adjustment of the incidence formula was performed
according to Hargrove et al. [13]. Specifically, adjustment
factors g and ε (g = 0.9348, refers to specificity of the BED
test over the period >2 times the window period, ε =
0.0652, refers to the rate of recent false-positives in those
with >2 times the window period, g + ε =1 )w e r ep r e -
viously found to be suitable for HIV incidence estimation
of diverse populations in China [8].
Results
The total number of people tested for HIV in each of
the five populations increased from 8084 in 2004 to
44,129 in 2008 (Additional file 1). The total number of
pregnant women tested increased from 4,944 in 2004 to
20,958 in 2006 and remained stable thereafter. Pre-mari-
tal couples were only offered HIV testing from 2006-
2008. Prevalence and incidence estimates were obtained
annually for each of the five focal populations (Figure 1).
IDUs
The estimated HIV prevalence was 45.4%, 43.8%, 41.8%,
44.3% and 38.4% and the estimated HIV incidence was
15.0%, 9.9%, 11.5%, 9.7% and 4.3% from 2004 to 2008,
respectively (trend test, P < 0.0001). HIV prevalence has
decreased from 2004 to 2008 (trend test, P < 0.0001);
however, it is still high in 2008. Changes in risk behavior
among IDUs in Dehong from 2004 to 2008 are dis-
played in Figure 2. Although needle-sharing and
commercial sex were still common, IDUs were more
likely to use condoms in the most recent years.
Discordant Couples
From 2004 to 2008, the HIV prevalence among the sex-
ual partners of HIV-positive individuals was 18.2%,
19.3%, 23.7%, 20.2% and 21.7%, while the estimated inci-
dence was 5.5%, 4.0%, 3.4%, 7.2% and 4.7%, respectively.
Neither prevalence nor incidence rates differed signifi-
cantly over time. Both remained stable at a relatively
high level from 2004 and 2008 (trend test, P = 0.23 and
0.75, respectively).
FSWs
The HIV prevalence among FSW showed a substantial
decrease from 5.5% in 2004 to 2.5% in 2008 (P < 0.001),
while the estimated incidence was 1.4%, 0.9%, 2.3%,
0.6% and 1.3%, and stayed at a relatively high level
throughout the study period (P = 0.45).
Pregnant Women
The cumulative number of HIV positive pregnant
women during the five-year period was 716. HIV preva-
lence among pregnant women was 1.0%, 0.8%, 0.9%,
0.8% and 0.7%, respectively, while estimated HIV inci-
dence remained stable throughout the five-year period
at 0.1%.
Pre-marital Couples
Between 2006 and 2008, the HIV prevalence for pre-
marital couples was 0.96%, 1.1% and 0.89%, while the
incidence was 0.16%, 0.16% and 0.13% among pre-mari-
tal couples, respectively. Both prevalence and incidence
remained stable over time (P = 0.31 and 0.36). The inci-
dence and prevalence among pre-marital couples
appeared somewhat higher than among pregnant
women but this difference was not statistically
significant.
The proportion of recent HIV-1 infections among
all HIV-1 positive participants
(See Additional file 2) Among all HIV-1 positive partici-
pants in all groups, the proportion of recent HIV-1
infections among females was higher than that among
males (from 12.32% in 2004 to 7% in 2008 for male, and
from 15.53% in 2004 to 15% in 2008 for female). As
expected for the largest ethnic group, the proportion of
recent HIV-1 infections was higher among Han Chinese
in 2004 compared to all ethnic minorities, but decreased
significantly over time through 2008 (trend test, P =
0.037). Dai and Jingpo are the main minority ethnic
groups living in Dehong, and approximately 10% of
HIV-positives were recent HIV-1 infections, with no
trend over time. Most HIV-1 positive participants were
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Page 3 of 8Figure 1 HIV prevalence and incidence among five populations in Dehong Prefecture, Yunnan Province from 2004 to 2008. Note: Black
rhomb indicates HIV-1 prevalence; black square indicates HIV-1 incidence.
Duan et al. BMC Public Health 2010, 10:180
http://www.biomedcentral.com/1471-2458/10/180
Page 4 of 8peasants and there was no change over time in the pro-
portion of recent HIV infections among this occupa-
tional group. In 2004, a comparatively large proportion
(31%) of participants with non-farming occupations had
recent HIV-1 infections, though this proportion
decreased over time (trend test, p = 0.001).
Discussion
T oo u rk n o w l e d g e ,t h i si st h elargest application of the
BED-CEIA to estimate HIV-1 incidence and the first
application among discordant and pre-marital couples
in China. Simulation of the HIV epidemic among IDUs
in Dehong from 2004 to 2008 showed that the epidemic
continues to expand but that the rate has been slowing
in the most recent years. Our incidence estimates sug-
gest that lower incidence may explain the slowing of
the growth of the epidemic among IDUs. The reasons
why HIV prevalence among IDUs remained stable while
the incidence decreased over the five-year period (but
still remained relatively high) may include several fac-
tors: 1) A high death rate among HIV-infected IDUs; 2)
High mobility among IDUs in Dehong and neighboring
areas with lower HIV prevalence; 3) The impact of local
government policies on strengthening the use of force
to combat drug abuse; 4) Temporal changes in the
number of newly developed IDUs and drug addiction
levels in different age groups. Finally, misclassification
of transmission route may also be a possible
explanation.
T h ee p i d e m i co fH I V / A I D Si nC h i n ac o n s i s t so fa t
least eight sub-epidemics [17] along with the spread of
other STDs, such as syphilis [18]. China’s HIV epidemic
remains low prevalence overall [19] with high infection
among specific sub-populations and in certain geo-
graphic areas such as Dehong Prefecture near the bor-
der with Myanmar [20]. Until recently, IDU was the
leading route of HIV transmission in China and HIV
continues to spread rapidly among IDUs in Dehong Pre-
fecture and other major drug trafficking corridors in
China [1-3]. However, the HIV transmission mode has
been changing gradually from IDU to sexual transmis-
sion. Our study demonstrates that HIV incidence
among IDUs in Dehong is decreasing. However, inci-
dence among the other four focal populations, all repre-
senting sexual transmission of HIV, has remained stable.
In our study, sexual transmission of HIV appears con-
centrated in several high-risk populations (especially
Figure 2 Prevalence of sexually transmitted diseases, self-reported commercial sex and risk behaviors among injection drug users in
Dehong Prefecture, Yunnan Province from 2004 to 2008. Note: From 2004 to 2008, condom use increased significantly (P < 0.0001), while
STD decreased (P = 0.02). Prevalence rates for needle sharing and commercial sex remained relatively stable (P = 0.28 and 0.99). Black rhomb
indicates needle sharing; black square indicates condom use; black triangle indicates sexually transmitted diseases; black cross indicates self-
reported commercial sex.
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stantially into the general population.
I nap r e v i o u ss t u d y ,w es h o w e dt h a tI D U sh a dt h e
highest HIV incidence rate in Yunnan Province, varying
between 2.2% and 8.0% from 2004 to 2008, and HIV-1
genetic diversity had become increasingly complex [2].
HIV incidence among IDUs in Dehong was also higher
than in other regions of China (except Xinjiang Province
in the Northwest) [8]. We speculate that the decrease in
incidence among IDUs may be partially explained by the
changes in risk behaviors, notably uptake in needle
exchange and a reduction in needle sharing [21]. While
there has been a notable increase in access to antiretro-
viral therapy among IDUs and some likely reduction in
AIDS- and drug-related deaths, more extensive model-
ing would be needed to estimate whether or not these
have also contributed to lower prevalence and incidence
estimates. After IDUs, negative persons in HIV-discor-
dant relationships had the next highest risk of transmis-
sion, with incidence estimated by BED varying from
3.4% to 7.2% and is very similar to that in a cohort
study of stable sex partners in Africa [22]. Because of
the high mobility of FSWs and the fact that many are
only in the business for a relatively short period of time,
the incidence and prevalence estimates in this group are
relatively close.
Since 2004, China Comprehensive Response Project
Areas were founded in Dehong, and a series of HIV
control and prevention efforts have been initiated,
including MMT, needle and syringe exchange, preven-
tion of mother-to-child transmission, and distribution of
free condoms as part of a 100% condom policy for sex
workers and their clients. Although coverage of inter-
vention programs has rapidly expanded in Dehong, the
HIV epidemic was likely influenced differently by these
various intervention efforts and we also found that the
reported needle sharing by IDUs did not markedly
decrease over the period of this study. Major challenges
to harm reduction include the high relapse rate for
MMT and the limited ability to reach the majority of
heroin users due to various barriers [21]. Therefore,
further multivariate analysis is needed to explore which
measures may be most effective for different popula-
tions. Our data emphasize the importance of accelerat-
ing HIV prevention programs like needle exchange and
MMT to reduce needle sharing among IDUs and con-
dom distribution and promotion to reduce unprotected
sex among discordant couples and among FSWs and
their clients.
T h e r ea r ean u m b e ro fd i f f e r e n tl a b o r a t o r ym e t h o d s
to estimate HIV incidence [23,24] and the use of these
methods is still evolving, especially in populations with
HIV-1 non-B subtypes. It is likely that BED-CEIA will
have its utility as a sensitive screening test, with avidity
used to exclude false positives, and modeling to further
estimate the remaining pool of false positives. The uti-
lity of the BED-CEIA assay has been demonstrated in
a number of studies, in particular for elucidating
trends in incidence [11,25,26]. Regional data from sub-
Saharan Africa on the use of BED have indicated that
it overestimates the HIV incidence [27] and further
adaptations have been made to enhance accuracy,
especially in populations infected with non-B subtypes
[13,28]. In the current study, the trend in incidence
among IDUs was very similar to that of a prospective
c o h o r ts t u d yc o n d u c t e di nt h es a m ea r e a[ 2 9 ] .T h e
prevalence and incidence among pregnant women and
pre-marital couples were very similar, with slightly
higher rates among pre-marital couples. These findings
indicate that the HIV incidence calculated from the
BED-CEIA assay is credible. This has previously been
shown also in another study from China [8]. We
excluded patients with CD4+ cell count ≤200 and
those on ART, as recommended [13]. This could lead
to a potential bias of the estimates because relatively
less vigorous exclusion was applied in the earlier years
than in late years during the period from 2004 to
2008. IDUs recruited from detoxification centers could
be an easier target for harm reduction programs than
IDUs in the community, which are generally harder to
reach; therefore, the trends of HIV incidence among
detoxification users may not reflect accurate trends
among non-detoxification users. Despite current lim-
itations, methods that allow cross-sectional HIV inci-
dence estimation are an important advance, and these
methods will be further refined as more experience is
gained in different settings. While absolute HIV inci-
dence estimates may be imperfect, they may still be
highly useful to determine trends over time [26,30,31].
Conclusions
A declining trend in HIV incidence among IDUs in
Dehong is encouraging, but with significant numbers of
individuals already infected and in need of treatment,
further roll-out of HIV care and treatment is needed
[32,33]. Prevalence and incidence of HIV infection have
stabilized at an unacceptably high level in Dehong Pre-
fecture, and special efforts are needed to reduce sexual
HIV transmission and to further increase the coverage
of MMT clinics and clean needle-syringe programs [34].
Further efforts are needed to strengthen monitoring and
evaluation of the epidemiological situation, to improve
the depth, breadth and innovation of intervention meth-
ods, to establish supportive policy and legislation, and to
strengthen international collaboration and information
exchange.
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Page 6 of 8Additional file 1: HIV prevalence and incidence among five
populations in Dehong Prefecture, 2004 to 2008. From 2004 to 2008,
the HIV prevalence among IDU and FSW showed a decrease. And the
estimated annual HIV incidence among IDU decreased significantly, while
remained stable among other focal populations.
Additional file 2: The proportion of the number of participants with
recent HIV-1 infection among HIV-infected participants in Dehong
Prefecture, Yunnan Province from 2004 to 2008. Among all HIV-1
positive participants in all groups, the proportion of recent HIV-1
infections among females was higher than that among males. The
proportion of recent HIV-1 infections was higher among Han Chinese in
2004 compared to all ethnic minorities, but decreased significantly over
time through 2008. Most HIV-1 positive participants were peasants and
there was no change over time in the proportion of recent HIV
infections.
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